AIM
AVXL icon

Acrospire Investment Management’s Anavex Life Sciences AVXL Stock Holding History

Acrospire Investment Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,796
Closed -$15K – 126
2017
Q2 		$15K Sell
2,796
-3,099
-53% -$17.9K 0.01% 1658
2017
Q1 		$34K Sell
5,895
-22,288
-79% -$115K 0.03% 1264
2016
Q4 		$112K Buy
28,183
+14,058
+100% +$50.1K 0.05% 841
2016
Q3 		$51K Sell
14,125
-75
-0.5% -$316 0.03% 1056
2016
Q2 		$87K Buy
14,200
+10,600
+294% +$51.2K 0.06% 575
2016
Q1 		$18K Buy
+3,600
New +$15.8K 0.01% 1562

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Acrospire Investment Management's AVXL Position: Q3 2017 in Review

Acrospire Investment Management sold out of Anavex Life Sciences (AVXL) in Q3 2017, closing a stake of 2,796 shares — an estimated $15K sold.

Acrospire Investment Management first reported a position in AVXL in Q1 2016 and held it in 6 quarters. The position peaked at $112K in Q4 2016. 62 funds tracked by Wall St. Rank hold AVXL as of Q3 2017.

  • Acrospire Investment Management reported no remaining Anavex Life Sciences position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 2,796 Anavex Life Sciences shares in Q3 2017, an estimated $15K.
  • Acrospire Investment Management first reported a position in Anavex Life Sciences in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Anavex Life Sciences position peaked at $112K in Q4 2016.
  • 62 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017.